Transcranial Near-infrared Light Therapy for Mild-Moderate Alzheimer's Disease (NIR4AD)

Prior treatment

• Contraindications to MRI, including pacemakers/defibrillators, ferromagnetic metal implants, etc;
• Individuals who are addicted to alcohol, drugs, or other drugs or have a tendency to become addicted;

Other illness

• Any neurological and psychiatric symptoms beyond the scope of symptoms that can be caused by Alzheimer's disease;
• A history of transient ischemic attack (TIA), stroke, or epilepsy within 12 months;
• MRI shows other clinically significant lesions, which may indicate the diagnosis of dementia beyond Alzheimer's disease;
• MRI shows other important pathological findings, including but not limited to: 4 or more microbleeds with a diameter of 10 millimeters or less; Single bleeding lesion with a maximum diameter greater than 10 millimeters; Surface iron deposition area; Evidence of exudative edema; Evidence of brain contusion, encephalomalacia, aneurysm, vascular malformation, or infectious disease; Multiple lacunar infarcts or strokes involving major vascular areas, severe small vessel or white matter lesions; Space occupying lesions; Or brain tumors (diagnosed as meningiomas or arachnoid cysts, lesions with a maximum diameter of less than 1 cm may not be ruled out);
• Severe visual or hearing impairment;
• Any other medical conditions that are not stable and adequately controlled (such as heart, respiratory, gastrointestinal, kidney diseases), or situations that the researcher believes may affect the safety of participants or interfere with the evaluation of the study;
• Other conditions that, in the opinion of the investigator, may not be suitable for this study.

Other

• Any mental diagnosis or symptoms that may interfere with the participant's research process (such as hallucinations, severe depression, or delusions);
• A photosensitive response to sunlight or visible light, with eczema or increased sensitivity on the skin at the intervention site;
• Participating in other AD clinical trials;

• 50 - 90 years old, no gender limitation;
• Meeting clinical diagnostic criteria of probable AD according to National Institute on Aging and the Alzheimer's Association (NIA-AA) guidelines;
• Clinical Dementia Rating Scale Total Score (CDR-GS) score ≥ 1 and ≤ 2, Clinical Dementia Rating Scale Memory Box score ≥ 0.5;
• Amyloid PET or cerebrospinal fluid examination or blood biomarkers conforms to changes in AD biomarkers;
• The MMSE score is ≥ 12 and ≤ 26;
• Education level is non illiterate or has received cultural education for 4-6 years or more;
• If taking mental or cognitive improvement drugs, the dosage must be stable for at least 3 months before the study, and remain unchanged during the light regulation intervention period. Unless otherwise specified, participants must consistently use all other (i.e. non Alzheimer's disease related) permitted concomitant medications for at least 4 weeks before baseline;
• Having a designated guardian or caregiver who can assist them in participating in the experiment (defined as someone who can support participants throughout the entire study period and spend at least 8 hours with them per week);
• Subjects with informed consent;